Trial intelligence / Profile preview

Upadacitinib versus methotrexate in adults with plaque or generalized morphea

IRCT20250228064873N4Phase 3Not yet recruiting

Sponsor: Tehran University of Medical Sciences
Start: Nov 2026
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial in morphea and generalized morphea comparing Upadacitinib group with Methotrexate group (2 arms). Primary endpoint: Localized Scleroderma Cutaneous Assessment Tool (LoSCAT). Planned start Nov 2026; status: not yet recruiting.

Drugs

upadacitinibmethotrexate

Conditions

morpheageneralized morphea

Beyond the preview

Go deeper on IRCT20250228064873N4.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20250228064873N4.